Galderma Group AG
Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
- Conditions
- Basal Cell Carcinoma
- Interventions
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 65
- Registration Number
- NCT00472108
- Locations
- 🇺🇸
Clinical Research Specialists Inc, Santa Monica, California, United States
🇺🇸Department of Dermatology, University of Minnesota Hospital and Clinic, Minneapolis, Minnesota, United States
🇺🇸Department of Dermatology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota, United States
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
- Conditions
- Basal Cell Carcinoma
- Interventions
- Drug: PlaceboDrug: PDT with Metvix 160 mg/g cream
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 66
- Registration Number
- NCT00472043
- Locations
- 🇦🇺
Dept. of Dermatology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Dermatology Dept., St. George Hospital, Kogarah, New South Wales, Australia
🇦🇺Dermatology Centre, Liverpool, New South Wales, Australia
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
- Conditions
- Actinic KeratosisBasal Cell CarcinomaWartsBowens DiseaseSquamous Cell Carcinoma
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 82
- Registration Number
- NCT00472459
- Locations
- 🇩🇰
Department of Dermatology, Roskilde Amysygehus, Roskilde, Denmark
🇩🇰Department of Dermatology, Århus Amysygehus, Århus, Denmark
🇩🇪Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte, Berlin, Germany
Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma
- Conditions
- Superficial Basal Cell Carcinoma
- Interventions
- Procedure: Hand held liquid nitrogen spray cryotherapy
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 120
- Registration Number
- NCT00469417
- Locations
- 🇦🇹
University of Graz, Graz, Austria
🇧🇪Universitaire Ziekenhuizen Leuven, Leuven, Belgium
🇫🇮Helsinki University Central Hospital, Helsinki, Finland
Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma
- Conditions
- Melasma
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 70
- Registration Number
- NCT00469183
- Locations
- 🇺🇸
Vitiligo and Pigmentation Institute of Southern California, Los Angeles, California, United States
🇺🇸University of Texas Southwestern Medical Center of Dallas, Dallas, Texas, United States
Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 302
- Registration Number
- NCT00469755
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Henry Ford Medical Center-Dept. of Dermatology, Detroit, Michigan, United States
🇺🇸Minnesota Clinical Study Center, Fridley, Minnesota, United States
Long-term Study of Efficacy/Safety of Adapalene/Benzoyl Peroxide Topical Gel in Acne Vulgaris Subjects
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 452
- Registration Number
- NCT00446043
- Locations
- 🇺🇸
Phoebe Rich, MD, Portland, Oregon, United States
Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris
- Conditions
- Acne Vulgaris
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 272
- Registration Number
- NCT00441415
- Locations
- 🇺🇸
Paul YAMAUCHI, Santa Monica, California, United States
🇺🇸Steven E. KEMPERS, Fridley, Minnesota, United States
🇺🇸Dr Alicia BUCKO, Albuquerque, New Mexico, United States
Subject Preference for Scalp Psoriasis Treatment
- Conditions
- Scalp Psoriasis
- Interventions
- Drug: C. propionate -Corticosteroid 3Drug: Corticosteroid 1- C. propionateDrug: C. propionate - Corticosteroid 1Drug: Corticosteroid 3 - C. propionateDrug: C. propionate- Corticosteroid 2Drug: Corticosteroid 2 - C. propionate
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 219
- Registration Number
- NCT00438399
- Locations
- 🇮🇹
Clinica Dermatologica Azienda Ospedaliera Policlinico di Modena, Modena, Italy
Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin
- Conditions
- Photoaged Skin
- Interventions
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 32
- Registration Number
- NCT00437320
- Locations
- 🇪🇸
Policlinico Ruber, Madrid, Spain
🇬🇧Whittington Hospital, London, United Kingdom
🇬🇧University of Manchester-Hope Hospital, Manchester, United Kingdom